Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales
This article was originally published in The Tan Sheet
Executive Summary
Significantly lower sales of GlaxoSmithKline's alli OTC weight-loss drug combined with struggles in the nicotine replacement therapy category weighed down the consumer health care division's performance in the firm's latest quarter
You may also be interested in...
FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
FDA adds kidney stones to the list of potential signals of a serious risk for alli based on AER information gathered between July and October 2011. GSK, which is confident in the safety and efficacy of alli when used correctly, placed the only OTC weight-loss drug on the auction block last April, but needs a buyer.
FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
FDA adds kidney stones to the list of potential signals of a serious risk for alli based on AER information gathered between July and October 2011. GSK, which is confident in the safety and efficacy of alli when used correctly, placed the only OTC weight-loss drug on the auction block last April, but needs a buyer.
GlaxoSmithKline's OTC Garage Sale Includes alli, FiberChoice
GlaxoSmithKline includes the alli weight-loss brand in its planned divestment of international OTCs worth about $813 million in 2010 sales, or 10% of the firm's total Consumer Healthcare business.